fluocinonide / Generic mfg. - LARVOL DELTA

Lymphocytic Esophagitis Presenting as Fibrostenotic Esophageal Disease Mimicking Eosinophilic Esophagitis in a Patient With Psoriasis (ACG 2026) - "Case Description/ A 74-year-old man with longstanding psoriasis managed with topical fluocinonide presented with progressive solid-food dysphagia for one year...(A) Low-power view of distal esophageal mucosa. (B) High-power view showing increased intraepithelial lymphocytosis with scattered eosinophils."

Clinical • Dermatology • Eosinophilic Esophagitis • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Immunology • Inflammation • Psoriasis

Phonophoresis for Enthesitis-Related Pain: Real-World Outcomes from a Retrospective Single-Centre Study (CRA-AHPA 2026) - " This retrospective single-centre study included patients treated with phonophoresis using fluocinonide 0.05% gel between November 2023 and May 2025... Phonophoresis was associated with clinically meaningful pain reduction across most anatomical sites, with adjunctive dry needling further enhancing outcomes. This noninvasive, well-tolerated treatment modality could serve as a useful adjunct for localized enthesitis-related pain, especially in patients unable to receive corticosteroid injections or for whom standard therapies are not ideal."

Real-world • Real-world evidence • Retrospective data • Musculoskeletal Diseases • Pain

Rapid Clearance of Lichen Planus With Topical Tapinarof. (PubMed, J Drugs Dermatol) - "To our knowledge, this is the first report in the literature showing successful treatment of LP with tapinarof. Further studies are required to determine if tapinarof is beneficial for the treatment of lichenoid diseases such as LP, lichen planopilaris, and others. &nbsp."

Journal • Contact Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology • Lichen Planus • Pruritus

Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study (clinicaltrials.gov) - P4 | N=250 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Aug 2026 ➔ Mar 2027 | Trial primary completion date: Mar 2026 ➔ Nov 2026

Trial completion date • Trial primary completion date • Alopecia • Dermatology • Immunology

First Report of Psoriasis Flare Following Pemigatinib Therapy for Cholangiocarcinoma (AAD 2026) - "Hydrocortisone was discontinued and treatment with fluocinonide 0.05% solution and ketoconazole 2% shampoo resulted in resolution of the scalp lesions. Known side effects of pemigatinib include ocular toxicity, hyperphosphatemia, and soft tissue mineralization[5]. To our knowledge, this is the first reported case of pemigatinib-induced psoriasis, highlighting the need for awareness of this potential adverse effect."

Biliary Cancer • Cholangiocarcinoma • Dermatology • Immunology • Infectious Disease • Metabolic Disorders • Mood Disorders • Nephrology • Oncology • Psoriasis • Renal Disease • Solid Tumor • FGFR

Drugs for atopic dermatitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) (clinicaltrials.gov) - P1 | N=86 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Phase classification: P1/2 ➔ P1 | Trial completion date: Nov 2026 ➔ Feb 2027

Phase classification • Trial completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery. (clinicaltrials.gov) - P4 | N=104 | Recruiting | Sponsor: Instituto Mexicano del Seguro Social | Trial primary completion date: Feb 2026 ➔ May 2027 | Not yet recruiting ➔ Recruiting

Enrollment open • Trial primary completion date • Genetic Disorders • Inflammation • Obesity • Pain

Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study (clinicaltrials.gov) - P4 | N=250 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Jan 2026 ➔ Aug 2026 | Trial primary completion date: Oct 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Alopecia • Dermatology • Immunology

Authors' Reply "Impact of Topical Fluocinonide on Oral Lichen Planus Evolution: Randomized Controlled Clinical Trial". (PubMed, Oral Dis) - No abstract available

Clinical • Journal • Dermatology • Dermatopathology • Lichen Planus

Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery. (clinicaltrials.gov) - P4 | N=104 | Not yet recruiting | Sponsor: Instituto Mexicano del Seguro Social

New P4 trial • Genetic Disorders • Inflammation • Obesity • Pain

The Sinister Side of 5 Alpha Reductase Inhibitor Use: Drug-Induced Melasma (CDA 2025) - "Finasteride and dutasteride, 5-alpha reductase inhibitors (5-ARIs), are off-label treatments for androgen-related conditions in women, and on-label treatments for androgenetic alopecia and benign prostatic hypertrophy in men...Case 1 : A 53-year-old healthy woman was prescribed oral finasteride (2.5 mg daily, later increased to 5 mg) and topical minoxidil compound for frontal fibrosing alopecia (FFA)...She was prescribed acitretin as a non-immunosuppressive alternative for her FFA. Case 2 : A 66-year-old male with a history of prostate pathology presented with one year history of melasma on his forehead and temples, treated unsuccessfully with hydroquinone, tretinoin, and fluocinonide. Despite trials of cysteamine, tretinoin, and oral tranexamic acid, his melasma persisted... These cases highlight the potential for 5-ARIs to induce melasma in both men and women taking finasteride without prior melasma. Dermatologists should consider this rare side effect when assessing..."

Alopecia • Benign Prostatic Hyperplasia • Dermatology • Dermatopathology • Fibrosis • Immunology • Sexual Disorders

Comment on "Impact of Topical Fluocinonide on Oral Lichen Planus Evolution: Randomized Controlled Clinical Trial". (PubMed, Oral Dis) - No abstract available

Clinical • Journal • Dermatology • Dermatopathology • Lichen Planus

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) (clinicaltrials.gov) - P1/2 | N=86 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting ➔ Recruiting | Phase classification: P2 ➔ P1/2 | Trial completion date: Jul 2026 ➔ Nov 2026 | Trial primary completion date: Jun 2026 ➔ Oct 2026

Enrollment open • Phase classification • Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Cutaneous Lupus Medication Experience Study (clinicaltrials.gov) - P=N/A | N=11 | Completed | Sponsor: Wake Forest University Health Sciences | Active, not recruiting ➔ Completed

Trial completion • Cutaneous Lupus Erythematosus • Immunology • Inflammatory Arthritis • Lupus

A case of folliculocentric extragenital lichen sclerosus: a rare variant and clinical presentation (AAD 2025) - "Two months later, she presented for a follow-up appointment, at which time she reported improvement of the lesions on the arms with fluocinonide 0.05% ointment and denied any new lesions...This case illustrates an unusual clinical presentation of this variant of LS&A, notably with the lack of hypopigmented lesions, and is the first case, to our knowledge, of this variant occurring simultaneously with genital LS&A. It further highlights the importance of considering folliculocentric extragenital LS&A in the differential diagnosis of follicular keratotic lesions on the extremities, which may aid in prompt diagnosis and management of LS&A."

Clinical • Dermatology • Inflammation

Dupilumab treatment for effective control of a Netherton's syndrome flare (AAD 2025) - "A 30-year-old female with a history of poorly controlled Netherton's syndrome presented with a severe flare for nearly three weeks following a twelve-day prednisone taper. On exam, the patient was found to be erythrodermic, with numerous, broad, confluent pink plaques accentuated by peripheral double-edged scale At the time of presentation, the patient was using fluocinonide 0.05% cream and emollients without relief and had a Peak Pruritus Numerical Rating Scale (PP-NRS) of 8. Given the recent history of steroid rebound and severity of disease, a trial of dupilumab, 600mg at the time of the visit, and 300mg administered every 14 days thereafter was initiated in combination with triamcinolone 0.01% cream twice daily...This case highlights the utility of dupilumab in providing rapid improvement in a patient actively experiencing a severe flare. Further studies defining the use of dupilumab in promptly resolving treatment-refractory Netherton's syndrome flares are..."

Dermatology • Pruritus

Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study (clinicaltrials.gov) - P4 | N=250 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Mar 2025 ➔ Jan 2026 | Trial primary completion date: Jan 2025 ➔ Oct 2025

Trial completion date • Trial primary completion date • Alopecia • Dermatology • Immunology

Treatment of Concomitant Alopecia Areata and Crohn's Disease in a Young Child With Tofacitinib: Case Report (AIBD 2024) - "Her alopecia did not respond to topical treatments with fluocinonide for the scalp, followed by Clobetasol...The development of AA following infliximab treatment and the timeline of the patient's symptom resolution suggests that the patient's alopecia likely developed secondary to her infliximab infusions. AA is an autoimmune disease mediates by cytotoxic T cell driven inflammation targeting hair follicles. Pediatric AA is the severe form of AA. Oral tofacitinib is a successful treatment for AA in adults and pediatric patients."

Case report • Clinical • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • JAK3

Targeting neurodevelopmental defects in Dravet syndrome mice rescues behaviour but not seizures and mortality. (AES 2024) - "Funding: - UCAJEDI (https://univ-cotedazur.fr/ucajedi-lidex-duniversite-cote-dazur, - ANR-15-IDEX-01, France), Laboratory of Excellence "Ion Channel Science and Therapeutics" - LabEx ICST (https://www.labex-icst.fr/en, ANR-11-LABX-0015-01, France) - EJPRD SCN1A-UP!...Furthermore, we assessed the importance of this developmental delay as pathological mechanism in Scn1a+/- mice rescuing GABA-switch by targeting either KCC2 or NKCC1 with the drugs KU55933 (KU) or bumetanide, respectively... We disclosed neurodevelopmental components in DS that selectively underlie some cognitive/behavioral defects, but not seizures, and we show that seizures and neuropsychiatric dysfunctions can be uncoupled and can have differential pathological mechanisms in DEEs. They could be treated separately with targeted pharmacological strategies."

Neurodevelopmental • Preclinical • CNS Disorders • Developmental Disorders • Epilepsy • Psychiatry • CDKN1A

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) (clinicaltrials.gov) - P2 | N=86 | Not yet recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Apr 2026 ➔ Jul 2026 | Trial primary completion date: Mar 2026 ➔ Jun 2026

Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Development and biopharmaceutical evaluation of aqueous micelle based corticosteroid formulations for topical treatment of oral lichen planus. (PubMed, Int J Pharm) - "The aims of this study were to develop aqueous micelle based formulations of triamcinolone acetonide (TA) and fluocinonide (FLU), using D-tocopheryl polyethylene glycol succinate, and to investigate corticosteroid delivery to the epithelium-lamina propria junction region - the anatomical target for OLP treatment - in comparison to that from marketed products. In contrast, the amounts deposited after applying Kenacort® A Orabase® and Novoter, were < LOQ. The results demonstrated that TPGS-based micelles improved mucosal bioavailability of TA and FLU in the epithelium-lamina propria junction region and might serve to improve topical OLP therapy."

Journal • Dermatology • Dermatopathology • Lichen Planus

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) (clinicaltrials.gov) - P2 | N=86 | Not yet recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Initiation date: Sep 2024 ➔ Dec 2024

Trial initiation date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Impact of Topical Fluocinonide on Oral Lichen Planus Evolution: Randomized Controlled Clinical Trial. (PubMed, Oral Dis) - "Topical fluocinonide 0.05% was more efficacious compared to placebo in reducing OLP outcomes at 6-month follow-up. Anxiety, depression, and stress were significant predictors of OLP outcomes and positively impacted the treatment with fluocinonide at 6 months."

Clinical • Journal • CNS Disorders • Depression • Dermatology • Dermatopathology • Lichen Planus • Mood Disorders • Psychiatry

Treatment Results for Patients with Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study (clinicaltrials.gov) - P4 | N=250 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Dec 2024 ➔ Mar 2025 | Trial primary completion date: Sep 2024 ➔ Jan 2025

Trial completion date • Trial primary completion date • Alopecia • Dermatology • Immunology